Stanley L. Garnett and Carrie E. Johnson of Brownstein Hyatt Farber Schreck have stepped in as defense counsel to radiopharmaceutical drug developer Cell>Point and its founders Greg R. Colip and Terry A. Colip in a pending SEC enforcement action. The complaint, filed June 10 in Colorado District Court, accuses the defendants of misleading investors regarding the status of the company’s clinical trials. The case, assigned to U.S. District Judge Philip A. Brimmer, is 1:21-cv-01574, U.S. Securities and Exchange Commission v. Cell>Point, LLC et al.

This suit was surfaced by Radar, a source for high-speed legal news and litigation updates personalized to your practice. Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]